Meet Our TED Community Partners

TED COMMUNITY ORGANIZATION, a nonprofit 501(c)(3) dedicated to thyroid eye disease (TED), serves as a vital hub for advocacy, support, education, and research, ultimately contributing to improved outcomes and a better quality of life for individuals affected by TED. We greatly appreciate the support of our partners as they make our important and impactful work possible.

How we help all who are affected by thyroid eye disease (TED).

Raise Awareness: Our nonprofit focused on thyroid eye disease can play a crucial role in increasing public awareness about TED. This can help educate people about the symptoms, risk factors, and available treatments, leading to earlier detection and better management.

Support and Advocacy: Thyroid eye disease can have a significant impact on individuals’ lives, affecting their physical and emotional well-being. TED CO can provide support services to affected individuals and their families, offering a sense of community, and understanding. Additionally, our organization can advocate for the needs and rights of individuals with TED, both within the healthcare system and in society at large.

Research Partnering: TED CO can contribute to medical research when relevant to our mission. We can raise awareness about research initiatives aimed at better understanding the causes of the disease, developing more effective treatments, and improving the overall quality of life for those affected.

Education and Resources: We can offer educational programs and resources for both patients and healthcare professionals. This may include workshops, seminars, online resources, and printed materials to help people better understand thyroid eye disease, its management, and the latest advancements in treatment.

Patient Assistance Programs: TED CO can point out resources available to assist patients who may be facing financial challenges in accessing necessary treatments, medications, or surgeries. This can ensure that individuals with thyroid eye disease receive the care they need, regardless of their financial circumstances.

Community Building: Creating a sense of community among individuals affected by thyroid eye disease can be invaluable. TED CO can facilitate support groups, online forums, and other community-building activities where individuals can share their experiences, exchange information, and provide emotional support.

Collaboration and Networking: TED CO can foster collaboration among researchers, healthcare professionals, and other stakeholders involved in thyroid eye disease. This collaborative approach can lead to a more robust lines of communication out to those who are suffering with thyroid eye disease. And can facilitate a comprehensive understanding of the condition and encourage the development of multidisciplinary approaches to its management, including a highly dynamic program for self-compassion and self-care.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. We bring our antibody engineering expertise to pioneering researchers with the intent to advance immunology breakthroughs into differentiated medicines for patients. Through collaboration, we have a common purpose and can accelerate discovery processes to bring solutions to patients who need them. argenx is currently working on a medication for thyroid eye disease (TED).

Viridian is a biopharmaceutical company focused on engineering and developing potential next-generation medicines for people living with autoimmune and rare diseases. Viridian is studying multiple potential new medicines in clinical studies for thyroid eye disease (TED) and advancing preclinical programs for other autoimmune conditions.

At Viridian, we are dedicated to creating solutions for people affected by autoimmune and rare diseases and have a team that is passionate and caring about this mission. We know that this work cannot be done in isolation and are committed to collaborating with the patient community to educate and raise awareness among all stakeholders, advance research, and establish impactful support initiatives to meet the unique needs of the communities we serve.

For more information, please visit www.viridiantherapeutics.com and follow Viridian on LinkedIn and X.

Sling Therapeutics is a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, focused on advancing an oral small-molecule therapy for thyroid eye disease. Its investigational drug, linsitinib, is the first and only oral IGF-1R inhibitor in Phase 3 development for TED, and has received FDA Fast Track Designation. In September 2026, Sling dosed the first patients in its global Phase 3 ORBIT trial and closed a $123 million Series C financing to support it. Sling is proud to partner with the TED Community in putting patients first.

We are a clinical-stage immunology company, dedicated to enabling normal lives for people with autoimmune diseases. As trailblazers in anti FcRn technology, we are developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.

Immunovant’s investigational product, imeroprubart (IMVT-1402), is a novel, fully human, monoclonal antibody that targets FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe this candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection with dosing that may be tailored based on disease stage and severity.

Prevent Blindness, a US organization, was established in New York in 1908 to prevent blindness and preserve sight for all ages. Its mission centers on public education, promoting improved public health systems, and advocating for public policy focused on early detection and eye care access. It aims to enhance early identification and treatment of vision disorders.

To address the lack of a program supporting patients in vision health, Prevent Blindness developed the ASPECT Program– Advocacy, Support, Perspective, Empowerment, Communication, and Training– which aims to strengthen our patient empowerment efforts for vision into a coordinated program that engages the individual in a more comprehensive manner. The goal of the ASPECT Program is to empower individuals to be engaged in their eye health from every direction and in every way.

Ethyreal Bio is a biotechnology company developing treatments for people living with Graves’ disease (GD) and Thyroid Eye Disease (TED).

The company’s lead program, ETHY-001, is an investigational therapy being studied as a possible treatment for both conditions. It is designed to block the thyroid stimulating hormone receptor (TSHR), which plays a key role in the disease process in both GD and TED.

By targeting TSHR, we hope to address the underlying cause of these diseases and help patients achieve lasting control of their symptoms. ETHY-001 is designed to be given as an injection under the skin (subcutaneous injection) and may only need to be given a few times a year.

Ethyreal is committed to listening to patients and working closely with doctors, researchers, and advocacy groups to help bring forward new treatment options that can make a meaningful difference for people affected by GD and TED.

ETHY-001 is investigational. Its safety and effectiveness have not been established, and it is not approved for any use by any regulatory authority.

For more information about Ethyreal Bio and our clinical trials, please visit https://clinicaltrials.gov/study/NCT07885605 or our website at www.ethyrealbio.com

Our Patient Advocacy team can be reached at patientadvocacy@ethyrealbio.com.

We are a biopharmaceutical company developing life-changing gene therapies for conditions affecting millions of people around the world. Our mission is to make gene therapies accessible – not just for the few – but for the many.

Kriya targets chronic diseases where AAV gene therapy could have a transformative impact, focusing on indications with significant unmet needs, validated clinical and regulatory endpoints, and well-understood disease biology.

Leveraging our expertise in protein engineering and computational biology, our product design process combines validated biology and intelligent vector engineering with the goal of creating durable therapies for our target diseases.

Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. We celebrate our unique history as the pioneers of scientific breakthroughs that have an incredible track record of improving lives. And yet, our ambitions are bigger and bolder. Together, we are united in a bold quest to solve the world’s most complex health challenges and serve society.

Leapcure starts by partnering with patient advocacy to connect patients with clinical trials. With an inclusive and values-driven approach, they are committed to empowering the patient voice to enhance the patient experience in clinical research. The approach delivers win-win-win results for all stakeholders in medical research; sponsors, sites, and patients alike. Leapcure helps achieve global breakthroughs for all. Heartfelt thanks to Leapcure for hosting the platform for the TED Community Organization CONNECTED 2025 and 2026 virtual global conference and Mini Summits.